Interestingly, tumors from mice that did not respond had a lower expression of CXCL14, and a loss of ability to express CXCL14 by CD11b+, a marker for monocytes, granulocytes, and NK cells, coincides with a loss of response to VEGF therapy and the return of tumor angiogenesis [119]. This evidence concerns the gene CXCL14 and neoplasm.